Ultragenyx Pharmaceutical (RARE) Accounts Payables (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Accounts Payables data on file, last reported at $42.0 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 11.49% year-over-year to $42.0 million in Q1 2026; TTM through Mar 2026 was $42.0 million, a 11.49% decrease from a year earlier, with the FY2025 full-year figure at $31.0 million, down 20.51% from the prior year.
• Accounts Payables for Q1 2026 stood at $42.0 million, up from $31.0 million in the prior quarter.
• Over the last five years, Accounts Payables for RARE reached as high as $59.8 million in Q2 2024 and fell as low as $23.5 million in Q3 2022.
• Historically, Accounts Payables has averaged $39.5 million across 5 years, with a median of $40.6 million in 2025.
• Across the five-year window, Accounts Payables soared 152.5% in 2022 and slumped 42.75% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $43.3 million in 2022, then slipped by 2.68% to $42.1 million in 2023, then slipped by 7.39% to $39.0 million in 2024, then fell by 20.51% to $31.0 million in 2025, then surged by 35.48% to $42.0 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $42.0 million in Q1 2026, $31.0 million in Q4 2025, and $40.6 million in Q3 2025.